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Summary The therapeautic efficacy of intact and F(ab')2 fragments of a "'I anti-CEA antibody were
compared in an established LS174T colonic xenograft model in nude mice. A single IV dose of either 0.5 mCi
(18.5 MBq) intact or 1.0 mCi (37 MBq) F(ab')2 fragments significantly delayed tumour growth, and increased
survival time to the same extent. Biodistribution studies showed that the more rapid clearance ofthe fragments
from the circulation improved the tumour:normal tissue ratios found for the intact antibody, but reduced the
duration and therefore absolute amount of radioantibody localisation (% injected dose/gram) at the tumour
site. The tumours received a similar accumulated beta radiation dose, with 4,065 cGy from 0.5 mCi intact
antibody and 4,500 cGy from 1.0 mCi F(ab')2 fragments. The dose rate to the tumour was initially higher for
the fragments, but fell off more rapidly as clearance occurred. However, the rapid circulatory clearance
resulted in a radiation dose of only 995 cGy to the blood, compared with 2,300 cGy for the intact antibody.
This suggests that twice the radiation dose could be delivered to the tumour in the form of fragments for the
same blood dose from the intact antibody. Fractionating the 1.0 mCi dose of F(ab')2 into three doses of
0.33 mCi (12.2 MBq), given on days 1, 3 and 5, significantly reduced the therapeutic effect of the treatment.
The clinical relevance of these findings is discussed.
The successful tumour localisation ofradiolabelled antibodies
raised against carcinoembryonic antigen (CEA), a tumour
associated marker of epithelial carcinomas, has led to the
investigation of radioimmunotherapy as a form of cancer
treatment in both animal xenograft models (Buchegger et al.,
1988; Sharkey et al., 1987; Pedley et al., 1991) and in man
(Begent et al., 1989; DeNardo et al., 1988). Antibodies
labelled with isotopes emitting medium- to high-energy beta
particules such as 13'I and 90Y are promising for solid tumour
therapy, because they can deposit their energy over a range
of more than 40 cells without requiring either binding to each
individual cell or internalisation.
However, a major drawback to the use of radioimmuno-
therapy is the potential damage to normal tissues from the
high doses due to circulating radioantibody. The more rapid
circulatory clearance and increased tumour penetration nor-
mally produced by antibody fragments make them an attrac-
tive alternative to intact antibody for tumour localisation and
therapy, although they do have the disadvantage of also
clearing more rapidly from the tumour itself.
We have previously reported on the comparative tumour
localisation and clearance patterns of intact IgG and
antibody fragments in the nude mouse model (Harwood et
al., 1985). The present study compares the therapeutic
efficacy of a radiolabelled intact antibody and its F(ab')2
fragments. We have compared the effect of a single dose of
"3'I-Fab(ab')2 A5B7, an anti-CEA antibody, with that of the
intact antibody on the colonic tumour xenograft LS174T
grown in nude (nu/nu) mice, and have related this to the
respective biodistribution and clearance patterns of the
antibodies. The effect produced on radioimmunotherapy by
fractionating the single dose of F(ab')2 A5B7 has also been
examined.
A dosimetric study, based on biodistribution and
clearance, has been carried out in order to compare the
observed therapeautic effect obtained for intact antibody and
fragments with the total radiation dose received by the
tumour and blood in each case. In order to demonstrate how
this accumulated total radiation dose was delivered over
time, dose rates to the tumour and blood from both the
intact A5B7 and the F(ab')2 fragments were also calculated
for selected time points after radioantibody administration.
Materials and methods
Antibodies
Radiolabelling Both intact and F(ab')2 fragments ofA5B7, a
monoclonal anti-CEA antibody (Pedley et al., 1987), were
labelled with "3iodine by the chloramine T method to a
specific activity of approx. 10 mCi mg-' protein, and passed
through a 0.22mm Gelman filter (Northampton, UK).
F(ab')2fragments These were prepared from a concentrated
solution ofA5B7 (20 mgml-') by pepsin (Sigma) digestion in
a 0.1 M sodium acetate solution, pH 4.5. Incubation was for
16-18 h at 37°C, and the reaction was terminated by dialysis
in PBS at pH 7.5. Antibody purification was carried out by
affinity chromatography using Protein A-sepharose (Phar-
macia), eluted with citrate buffer pH 3, followed by gel filtra-
tion on Sephacryl S-200 (Pharmacia) to separate the F(ab')2
fragments. Purity was checked by SDS-PAGE. The intact
ASB7 and the F(ab')2 fragments are in regular clinic use for
both localisation and therapy studies.
Animal studies
Xenografts A human colon adenocarcinoma cell line
LS174T (Tom et al., 1976) was used to develop a xenograft
tumour model in the flank of female nude (nu/nu) mice by
subcutaneous cell inoculation. Subsequent passaging was by
continuous subcutaneous implantation from the original
xenograft. All mice used were 2-3 months old, with a weight
of between 20-25 g. The tumour is a moderately
differentiated CEA-producing adenocarcinoma with small
glandular acini, which secretes no measurable CEA into the
circulation. ASB7 gives positive staining for the glandular
luminal surface and cytoplasm in the LS174T xenograft, and
there is also some reactivity with necrotic debris and glan-
dular contents.
Radioimmunotherapy studies The experiments proceeded
when the tumours were between 0.1-0.2 cm3 in volume and
in exponential growth (10-14 days after passaging), using 6
mice per group. All antibody administration was via the tail
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vein. For single dose therapy the mice were given either
0.5 mCi of intact antibody or 1.0 mCi of F(ab')2 fragments,
calculated from previous preliminary distribution studies (not
shown) by the trapezoidal rule to give the same total radia-
tion dose to the blood (Jeffrey, 1985). Fractionated therapy
was given as three doses of fragments (0.33 mCi per dose) on
days 1, 3 and 5, chosen because doubling time for the
tumour was 2-3 days. Control mice received no antibody.
The mice were weighed and the tumours measured on the
day of antibody injection, and on every subsequent 3rd or
4th day, until the tumours exceeded 2cm3. Tumours were
measured in three dimensions (L, W & H), and the volume
calculated as LWH/2 (Looney et al., 1973).
Antibody biodistribution For comparative biodistribution
studies either intact of F(ab')2 A5B7 antibody (50pCi/5 1Lg)
was administered intravenously, using four mice per group.
The mice were bled and killed at selected time points, and the
following organs removed for activity assessment on the
gamma counter (LKB, Bromma, Sweden, Wallac 1282 Com-
pugamma): blood, liver, kidney, lung, spleen, colon, muscle
and tumour. Animals were given food and water ad libitum,
the water containing 0.1% potassium iodide during
experiments in order to block thyroid uptake of iodide.
Statistical analysis Comparison of survival between treat-
ment groups, calculated as time taken for the tumours to
reach 2 cm3, was performed by the non-parametric Lee-Desu
statistic (Lee & Desu, 1972). 'Significant' indicates a P value
of below 0.05.
Dosimetry
This was calculated as previously described (Pedley et al.,
1989). In brief, for each biodistribution time point of A5B7
and F(ab')2 A5B7 the counts per gram for blood and tumour
were re-normalised in terms of injected activity. Clearance
curves were then constructed from the percentage activity
remaining, displaying the combined effects of both radionuc-
lide decay and organ clearance. By relating each initial value
of counts per gram to the injected activity, the percentage of
initial administered activity (PIA) was obtained for each
organ. For each of the antibodies used, the fractional beta
dose delivered to each tissue during successive elements of
the clearance curve were computed using a standard equation
for dosimetry in tissue (MIRD Pamphlet No. 11, 1975). The
total beta dose to 144 h (DP) was then obtained by summa-
tion of all these fractional dose elements. Using the derived
values of PIA and DP, the individual tissue doses were
calculated for the antibodies.
Dose rates (cGy h-) delivered at the tumour site and to
blood by both the intact and F(ab')2 A5B7 at selected time
points after radioantibody administration were also deter-
mined using the same MIRD calculations.
Results
The data presented are representative of a series of
experiments giving similar results.
Single dose radioimmunotherapy
Figure 1 shows the mean tumour growth following either
0.5 mCi intact '13I A5B7 or 1.0 mCi F(ab')2 fragments. Both
these treatments produced a significant therapeutic effect
when compared with the group receiving no treatment
(Figure 1). Tumour growth was inhibited for 28 days in the
case ofintact A5B7, and for 26 days in the case offragments.
When the two therapy groups were compared, there was no
significant difference between the prolonged survival effects
produced by each treatment. Administration of unlabelled
intact antibody or F(ab')2 fragments had no effect on tumour
growth or animal survival time (not shown).
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Figure 1 Effect of various treatment regimes on growth of
LS174T tumours. (1) 0.5 mCi '3ll-A5B7 (87 + 24); (2) 1.0 mCi
'31-A5B7 F(ab')2 (79 ± 23); (3) untreated (35 + 12). Vertical bars
indicate s.e.m. Mean group time for tumour to reach 2 cm3 ± s.d.
(days) in parenthesis. Six mice per group.
Multiple dose radiotherapy
Figure 2 shows the effect on therapy of fractionating the
single 1.0 mCi dose of F(ab')2 A5B7 in three doses of
0.33 mCi each, given on days 1, 3 and 5. Both treatment
groups again showed significant inhibition of tumour growth
and prolongation of survival when compared with the group
receiving no treatment (Figure 2). However, fractionating the
therapy dose significantly reduced the survival of mice when
compared with those receiving the same total radiation dose
as a single injection. This was borne out by the tumour
growth inhibition following treatment, which was 21 days
when the therapy was given as a single dose, but only 10
days after fractionation.
Adverse effects oftreatment
A slight loss in group mean weight following treatment with
intact radioantibody was found, though this never exceeded
10% of total body weight for any individual. Animals receiv-
ing fragments did not suffer weight loss, but some did cease
to gain weight. In all cases normal weight was regained by 2
weeks after treatment, there was no evidence of any long-
term toxicity up to 120 days post treatment, and there were
no premature deaths before the tumours reached 2 cm3 and
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Figure 2 Effect of various treatment regimes on growth of
LS174T tumours. (1) 1.OmCi 131I-A5B7 F(ab')2 (77 ± 18); (2)
3 x 0.33 mCi '3II-A5B7 F(ab')2 (48 ± 7); (3) untreated (22 ± 9).
Vertical bars indicate s.e.m. Mean group time for tumour to
reach 2 cm3 + s.d. (days) in parenthesis. Six mice per group.RADIOIMMUNOTHERAPY WITH INTACT vs F(ab')2 ANTI-CEA ANTIBODY 71
the mice were culled. No histological evidence of radiation
damage to normal tissues was observed.
Biodistribution studies
The tissue distribution and clearance of intact and F(ab')2
fragments of ASB7 were compared over a period of 6 days
(Figure 3). By 6 h post injection the F(ab')2 fragments
already showed significantly faster clearance from the circula-
tion than the intact antibody (12.8% injected activity dose
(ID)/g compared with 24%). The other normal tissues also
showed reduced activity, but tumour levels were not
significantly different at this time (10.9%:14.4%). The rapid
clearance of F(ab')2 fragments from normal tissues continued
over the 6 days, but the tumour retention was reasonably
good. Although the intact antibody showed superior tumour
localisation, the concomitantly slower normal tissue clearance
resulted in lower tumour:blood ratios than were found for
the fragments (0.6 compared with 0.9 at 6 h, 1.4 compared
with 3.7 at 24 h, and 2.2 compared with 8.4 at 144h).
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Figure 3 Tissue distribution over time of 50psCi/5 jug intact and
F(ab')2 A5B7 in the LS174T colonic tumour model in nude mice.
Results are expressed as percentage of antibody dose g ' of
tissue, and are the means of four mice. Vertical bars indicate s.d.
(<0.2% not shown). Hatched: intact A5B7, Black: F(ab')2
A5B7.
Dosimetry
Table I shows that cumulative beta radiation dose delivered
to tumour and blood from a single dose of either 0.5 mCi of
intact or 1.0 mCi F(ab')2 '31I-A5B7, and compares them with
figures previously calculated for 0.5 mCi of the polyclonal
anti-CEA antibody PK4S. These data confirm that the
similar therapeutic effects produced by 0.5 mCi intact and
1.0 mCi F(ab')2 fragments of A5B7 (Figure 1) resulted from
the delivery of a similar radiation dose to the tumour in each
case (4,065 cGy for the intact antibody and 4,500 cGy for the
fragments). However, the blood received less than half of the
cumulative dose when given in the form of fragments (995
cGy compared with 2,300 cGy for intact antibody), even
though double the activity of the intact antibody had initially
been administered. When the dosimetry of the intact mono-
clonal ASB7 was compared with that of the polyclonal PK4S
the blood dose was similar, but that delivered to the tumour
was inferior for the polyclonal (2,348 cGy), reflecting the
inferior tumour localisation and therapy previously found for
that antibody (Pedley et al., 1991).
The dose rates delivered to tumour and blood at selected
times after administration of either 0.5 mCi intact or 1.0 mCi
F(ab')2 A5B7 are shown in Table II. At 6 h the two treat-
ments were giving a similar radiation dose to the blood, but
by 24 h the dose rate from the '3"I-F(ab')2 was already
reduced to a third ofthe intact rate, the latter remaining high
throughout the experiment. The dose rate to tumour from
the fragments was initially higher than that produced by the
intact antibody (40 cGyh-' compared with 26.6 cGyh-' at
6h), but fell off rapidly with time. That from the intact
antibody peaked at 24 h (38.4 cGy h-'), followed by a more
gradual decline in dose rate over the 6 days. These activity
patterns reflect the antibody biodistribution and clearance
shown in Figure 3.
Discussion
We have previously shown that a single 0.5 mCi intravenous
injection of either "3'I-labelled monoclonal (A5B7) or poly-
clonal (PK4S) anti-CEA antibody significantly inhibited the
growth of a well established colonic xenograft in nude mice,
and caused temporary tumour regression. Radiolabelled non-
specific antibody delayed tumour growth for a few days only,
with no significant increase in survival time, while unlabelled
specific antibody had no effect on tumour growth (Pedley et
al., 1991).
The present results demonstrate that twice the activity of
radioantibody must be administered as F(ab')2 fragments in
order to produce the same therapeutic effect as the intact
antibody (Figure 1). This is because the more rapid cir-
culatory clearance of fragments via the kidney during the
initial few hours after administration (Figure 3) results in a
lower absolute amount to the tumour when compared with
Table I Estimated P radiation dose (cGy) to blood and tumour
from intact (0.5mCi) and F(ab')2 (1.OmCi) I3l-labelled anti-CEA
antibody
Tissue F(ab')2 A5B7 Intact A5B7 Intact PK4S
Blood 995 2,300 2,191
Tumour 4,500 4,065 2,348
T:B ratio 4.5:1 1.8:1 1.1:1
Table II Estimated dose rates (cGy h-') to blood and tumour from
intact (0.5 mCi) and F(ab')2 (1.0 mCi) A5B7 at selected times after
antibody administration
Intact A5B7 F(ab')2
Time Blood Tumour Blood Tumour
6 h 44.3 26.6 47.2 40.0
24 h 27.2 38.4 8.7 32.4
144 h 10.0 22.1 1.3 10.772 R.B. PEDLEY et al.
the intact antibody. An advantage of this, however, is the
increased tumour:normal tissue ratios found for the
fragments at all time points studied, and also the possibility
of administering larger amounts of radioantibody before a
similar level of toxicity to the bone marrow, the most
radiosensitive tissue, is reached. This tolerance to high doses
of F(ab')2 fragments is shown by the maintenance of body
weight in mice receiving this treatment, while those with only
half the dose of intact antibody exhibited transient weight
loss. It should be remembered that the whole body gamma
dose, which is more representative of the activity received by
the bone marrow, would only be 10% or less of the blood
dose for a small animal such as the mouse compared with
35-40% in the case of man. In a comparative therapy study
using fractionated anti-CEA antibodies in a colon xenograft
model, Buchegger et al. (1990), calculated that 4-5 times
more '3'I F(ab')2 than intact antibody was required in order
to achieve the same radiation dose to the tumour. The
former did, however, produce superior therapeutic results,
suggesting that the tumour dose may be an underestimate. In
agreement with the present work, he also found that the
fragments were less toxic than the intact antibody although
they were administered in larger amounts.
Dosimetry calculations, based on a more detailed study of
early biodistribution of F(ab')2 A5B7 in the LS174T model,
suggest that a total 1B radiation dose of 995 cGy was delivered
to the blood, while the tumour received 4,500 cGy, for each
mCi administered (Table I). The equivalent figures for the
0.5 mCi dose of intact antibody were 2,300 cGy to the blood
and 4,065 cGy to the tumour. These calculated tumour doses
are borne out by their similar therapeutic effects, shown in
Figure 1. The reduction in dose to the blood from fragment
administration indicates that four times the dose of intact
antibody (i.e. 2mCi) could safely be administered in the form
of F(ab')2 fragments, which should double the therapeutic
effect produced in the present experiments. These dosimetry
results are in close agreement with those of Buchegger et al.
(1989), who calculated that a single 2.2 mCi injection of
anti-CEA F(ab')2 fragments in a colonic xenograft model
delivered 8,335 cGy to the tumour and 2,093 cGy to the
blood. This produced complete remission in all of the mice
treated, although some bone marrow transplantation was
required. We have already achieved an inhibition of tumour
regrowth for 26 days after a single dose of 1 mCi F(ab')2
fragments, and therefore we are now carrying out dose
escalation studies which should significantly improve this.
The higher cumulative radiation dose to the tumour pro-
duced by the intact monoclonal '311-A5B7 when compared
with the polyclonal "311-PK4S (Table I) is in agreement with
both the superior tumour localisation and therapeutic effect
found for the monoclonal antibody in previous experiments
(Pedley et al., 1991).
Fractionating the same dose of F(ab')2 fragments signifi-
cantly reduced the therapeutic effect of the treatment when
compared to administration as a single dose (Figure 2). Some
authors suggest that fractionation is at least as effective as
the administration of a single high dose of radioantibody and
may be less toxic to the host (Buchegger et al., 1989; Schlom
et al., 1990), but -this can depend on a variety of factors
including the number and timing of doses, tumour doubling
time and the size of the initial dose. We found that the
tumour to blood ratio produced by the three fractionated
doses at 144 h was inferior to that resulting from the single
I mCi dose (3.0:1 cp 8.4:1), so alternative timing regimes for
antibody administration will be investigated. We will also be
looking at fractionation as a way of delivering higher doses
of fragments which would be toxic if delivered in a single
administration. Dose fractionation may be of greater impor-
tance in radioimmunotherapy using intact antibody, where
toxicity is a more serious problem, but repeated antibody
delivery will increase the development of HAMA responses
in patients.
The timing of maximum activity delivery to the tumour at
the time points studied differed for the intact and F(ab')2
fragments, and was consistent with the more rapid equilibra-
tion between plasma and extracellular fluid for the F(ab')2
than for the intact antibody (Table II). The earlier peak and
more rapid clearance in tumour localisation found for the
F(ab')2 gave maximum dose rate at 6 h after antibody
administration, while the slower localisation but prolonged
tumour retention of the intact antibody gave a peak rate at
24 h with prolonged delivery over 6 days. The tumour
appears to require a high initial dose of radiation in order to
kill enough cells for effective therapy. As the dose rate of
beta radiation is lowered its effectiveness is also reduced,
because tumour growth rate can exceed the cell kill rate and
also more time is available for repair of the sublethal damage
while the dose is still being delivered (Fowler, 1990). The
fragments therefore need to be administered at double the
intact antibody activity in order to achieve the same inhibi-
tion of tumour growth. The effect of fractionating the frag-
ment dose was to reduce the peak rate at 6 h from 40cGy
h-' to 13.3 cGy h-'. Repeating this dose on days 3 and 5, in
order to kill newly dividing cells, did not counteract the effect
of both reduced cell kill resulting from the lower initial dose
rate and interim repair of sublethal radiation damage during
the 48 h periods between radioantibody administrations. The
outcome, therefore, was reduced therapeutic efficacy, even
though the total administered dose of "'lI F(ab')2 was the
same in each case.
The early attainment of maximum dose rate for the F(ab')2
fragments suggests that a radionuclide with a short half life
to match this biological clearance, such as 9Y, would be
suitable for this type of therapy, while the pattern seen for
the intact antibody, where the high dose rate is given over a
longer period, is more compatible with the use of '3'I with a
half life of 8 days. Dose rates delivered to the blood from the
intact or F(ab')2 ASB7 followed the patterns seen for the
tumour (Table II). The rapid circulatory clearance of the
fragments significantly reduced the time during which the
bone marrow was subjected to a high radiation dose when
compared to the intact antibody. By 24 h the dose rate to
blood for the intact antibody was 27.2 cGy h', while that
for the F(ab')2 had already fallen to 8.7cGyh1'.
Much of the published work may underestimate the value
of radioimmunotherapy. Despite the theoretical inadequacy
of radiation doses achieved to the tumour when compared to
external beam radiotherapy, responses have been seen in
both animals and patients (Cheung et al., 1986; Sharkey et
al., 1987, Begent et al., 1989). Low-dose-rate intracavity and
interstitial radioactive implants give figures of about
50cGy h'-, while the dose rate from radioimmunotherapy is
generally around 10-20 cGy h- (Fowler, 1990). This would
not, therefore, be considered sufficient for a significant
therapeutic effect to be observed, particularly if the tumour
combines a short doubling time with a low intrinsic radiosen-
sitivity (Dale, 1989). In the present situation, however, with
good antibody localisation in the tumour, double this dose
rate is delivered by both intact antibody and F(ab')2
fragments for at least the first day or two after administra-
tion (Table II), and so the observed therapy results are in
agreement with these figures. Radioimmunotherapy also has
the advantage of the dose being delivered over a few days
rather than weeks, especially in the case of rapidly pro-
liferating tumours, while the heterogeneous microdistribution
of the antibody may give selectively higher than estimated
doses to the viable areas of the tumour (Humm & Cobb,
1990). Results in patients should be improved if smaller
tumours are treated, because radioantibody uptake is
inversely related to tumour size (Pedley et al., 1987). The
present increase in therapeutic ratio found for F(ab')2
fragments, and the subsequent possibility of employing
higher doses of radioantibody in this form without increasing
the radiation damage to bone marrow, should therefore be of
relevance in improving future patient treatment, with or
without adjuvant therapy. It must be borne in mind that the
circulatory clearance of radioantibody can differ between
mice and man, and that the latter will receive a higher
gamma dose to the whole body with lower bone marrow
tolerance to radiation (Buchegger et al., 1989; Begent &RADIOIMMUNOTHERAPY WITH INTACT vs F(ab')2 ANTI-CEA ANTIBODY 73
Pedley, 1990). However, the good correlation we have
achieved between observed therapeutic results and calculated
radiation doses delivered to the tumour confirms the
suitability of this model for the assessment of future radio-
immunotherapy modalities prior to clinical trials.
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